Navigation Links
Anthera Pharmaceuticals to Present at Deutsche Bank Securities' 35th Annual Health Care Conference
Date:4/26/2010

HAYWARD, Calif., April 26 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced Paul F. Truex, Anthera's President and Chief Executive Officer will present at the Deutsche Bank 35th Annual Health Care Conference in Boston, MA on Monday, May 3, 2010 at approximately 9:20 am Eastern Time.  

To access live audio broadcasts of these presentations, or the subsequent archived recordings, log onto http://www.anthera.com.  Please connect to the website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.  

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 ready clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases suc
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
2. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
3. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
5. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
8. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
9. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
11. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... BURLINGTON, Mass. , June 18, 2013 Decision ... for pharmaceutical and healthcare issues, finds that, over the past ... ( France , Germany , ... and the United Kingdom ) have been ... most of their HIV patients, primarily to reduce costs. Additionally, ...
(Date:6/18/2013)... NEW YORK , June 18, 2013 JDRF ... ) are accelerating the development of new products that combine ... new collaboration announced today. This new, three-year commitment is an ... (T1D). Many patients with T1D not only take ... to be placed in the body for a number of ...
(Date:6/18/2013)... 2013 Today, Wall Street Reports announced ... GILD ), Health Management Associates Inc. (NYSE: HMA ... Pharmaceuticals Inc. (NASDAQ: ISIS ), and Trius Therapeutics ... of charge - including full price targets, industry analysis and ... Sciences, Inc. Research Report On June 7, 2013, ...
Breaking Medicine Technology:One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 2One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 3JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 2JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6
... announces that a new market research report is ... Urological Catheters Industry http://www.reportlinker.com/p087354/Global-Urological-Catheters-Industry.html ... worldwide markets for Urological Catheters in Thousand Units ... Dialysis Catheters (Hemodialysis, & Peritoneal), and Urinary Catheters ...
... Inc., a full service contract biomanufacturing company, today ... Development and Manufacturing Agreement with a multinational biopharmaceutical ... the process to manufacture a unique therapeutic monoclonal ... will be manufactured under cGMP conditions as a ...
Cached Medicine Technology:Reportlinker Adds Global Urological Catheters Industry 2Reportlinker Adds Global Urological Catheters Industry 3Reportlinker Adds Global Urological Catheters Industry 4Reportlinker Adds Global Urological Catheters Industry 5Reportlinker Adds Global Urological Catheters Industry 6Reportlinker Adds Global Urological Catheters Industry 7Reportlinker Adds Global Urological Catheters Industry 8Reportlinker Adds Global Urological Catheters Industry 9Reportlinker Adds Global Urological Catheters Industry 10Reportlinker Adds Global Urological Catheters Industry 11Reportlinker Adds Global Urological Catheters Industry 12Reportlinker Adds Global Urological Catheters Industry 13Reportlinker Adds Global Urological Catheters Industry 14Reportlinker Adds Global Urological Catheters Industry 15Reportlinker Adds Global Urological Catheters Industry 16Reportlinker Adds Global Urological Catheters Industry 17Reportlinker Adds Global Urological Catheters Industry 18Reportlinker Adds Global Urological Catheters Industry 19Reportlinker Adds Global Urological Catheters Industry 20Reportlinker Adds Global Urological Catheters Industry 21Reportlinker Adds Global Urological Catheters Industry 22Reportlinker Adds Global Urological Catheters Industry 23Reportlinker Adds Global Urological Catheters Industry 24Reportlinker Adds Global Urological Catheters Industry 25Reportlinker Adds Global Urological Catheters Industry 26Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement 2
(Date:6/18/2013)... Biomet hip lawsuit claims ... in a multidistrict litigation in U.S. District Court, Northern ... to court records, the litigation’s most recent status conference ... Court also convened a motions hearing and a tutorial ... Biomet hip replacement litigation. The proceeding’s next Status ...
(Date:6/18/2013)... 18, 2013 Seven-year-old Riley Salz of ... autism. He receives 40 hours a week of applied ... from the Center for Autism and Related Disorders (CARD). ... 2008, and has experienced remarkable progress, including learning to ... environment. Riley’s personal journey through autism is now featured ...
(Date:6/18/2013)... cells have a much different and more complex ... University of Texas at Dallas have found that exploiting ... lung cancer. , In an article published online May ... Dallas researchers compared the metabolic characteristics of non-small-cell lung ... same patient. , They found that the cancer ...
(Date:6/18/2013)... using technology developed at Case Western Reserve University,s ... of Engineering, has made available avatarsvirtual patientsto train ... and others training to evaluate speech-language disorders to ... on the trainee, because a diagnosis doesn,t have ... , Graduate students studying to become speech-language pathologists ...
(Date:6/18/2013)... More than 1.1 million people in the U.S. ages 13 ... for Disease Control and Prevention (CDC). Of those, nearly 20 ... HIV Testing Day on June 27, Allsup, a nationwide provider ... CDC and other organizations are raising awareness of the importance ... new HIV infections each year. Along with developing AIDS, those ...
Breaking Medicine News(10 mins):Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:SimuCase avatars advance speech-language pathology training 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3
... , , , ... Sterling Communications Inc. , an independent, full-service, high-tech ... Knome to its client portfolio of industry-leading technology ... Knome has turned to Sterling to create a communications strategy ...
... , , , OCEANSIDE, N.Y., ... DEKAYE Consulting, Inc., announced the publication of his newest article, ... in the June 30, 2009 and July 14, 2009 issues of ... 12-13 and 12-14). Mr. DeKaye serves on the publication,s editorial ...
... Aug. 3, 2009 The new anti-wrinkle facial filler Dysport, ... reduced frown lines between the eyes, according to users and ... Southwestern Medical Center. "Our study confirmed that Dysport (abobotulinumtoxinA) ... Dr. Rod Rohrich, chairman of plastic surgery at UT Southwestern ...
... study finding suggests insulin treatment could boost the risk ... of the most widely used diabetes drugs, may offer ... pancreatic cancer by 60 percent, a new study shows. ... treatments, including the use of insulin or insulin-releasing medications ...
... , , LAS VEGAS, ... that expressdelivery.biz is a trusted merchant and its ability to honor ... have been verified by buySAFE. This certificate from the all-bonded online ... reliable and smooth online purchases with bond guarantees of up to ...
... , , CHICAGO, July 30 ... the leading global provider of risk management ... and Beverage Industry Report . The first annual report was ... remain abreast of emerging issues and learn how peers and competitors ...
Cached Medicine News:Health News:Knome Selects Sterling Communications as Agency of Record 2Health News:New DeKaye Article Identifies 'Hierarchy of Greed' in Healthcare Fraud 2Health News:New DeKaye Article Identifies 'Hierarchy of Greed' in Healthcare Fraud 3Health News:New DeKaye Article Identifies 'Hierarchy of Greed' in Healthcare Fraud 4Health News:Dysport proves safe, effective anti-wrinkle treatment, UT Southwestern plastic surgeons find 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 3Health News:US Discount Online Pharmacy Expressdelivery.biz Can Guarantee Safe and Enjoyable Shopping Experience With buySAFE Certificate 2Health News:Increasing Regulation and Economic Volatility Key Catalysts for Risk Management in the Food System, Agribusiness and Beverage Industry, Says Report from Aon Analytics 2Health News:Increasing Regulation and Economic Volatility Key Catalysts for Risk Management in the Food System, Agribusiness and Beverage Industry, Says Report from Aon Analytics 3Health News:Increasing Regulation and Economic Volatility Key Catalysts for Risk Management in the Food System, Agribusiness and Beverage Industry, Says Report from Aon Analytics 4
... The Clariflex® Intraocular Lens is indicated ... years of age or older in whom ... IOL is a third-generation IOL design made ... is designed both to reduce internal reflections ...
... Lenses: The Bausch & Lomb PMMA Posterior Chamber ... primary implantation for the visual correction of aphakia ... where a cataractous lens has been removed by ... be placed in the ciliary sulcus or capsular ...
... USIOL lenses are manufactured using ... processes. Perspex CQ UV PMMA ... multi-piece and single piece lenses. ... in both nonphaco and phaco ...
... II is a sterile nonpyrogenic, transparent viscoelastic ... II contains 12 mg/ml of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
Medicine Products: